The FDA has approved a liquid formulation of the prescription antihistamine Xyzal (levocetirizine dihydrochloride, from UCB and sanofi-aventis). The 0.5mg/mL strength of Xyzal oral solution is expected to be available for the 2008 Spring allergy season in addition to the tablet formulation already available. Xyzal is indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and the treatment of chronic idiopathic urticaria.

For more information call (888) NOW–XYZAL or visit www.xyzal.com.